Skip Navigation LinksHematology

​​​​​​​​​​​​​​​​Hematology Trials


Cancer Control/Prevention

U10055: Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-Up

Lymphoma, Hodgkin's​

C50801:  Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)​

Lymphoma, Non-Hodgkin's

​​Diffuse Large B-cell​

RU051417I: Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide (R2-ICE) in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Follicular

​Mantle Cell


Plasmablastic

Lymphoma, Hodgkin's


Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia
​​E1912: A Randomized Phase III Study of Ibrutinib(PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).​​

UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

UTX-TGR-204: A Multi-Center, Open-Label, Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

​Chronic Myelomonocytic Leukemia

​CONNECT MDS AML: ​The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry


Myelodysplastic Syndrome Chronic

Multiple Myeloma

E1A11:  Randomized Phase III Trial of Bo​rtezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Sy​mptomatic Multiple Myeloma (ENDURANCE)

S12​11​​: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)​​

Insight (NSMM-5001): ​Global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study

A061202: Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib VS. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy